Abstracts tagged "prednisone"

Abstract Number: L16 • 2019 ACR/ARP Annual Meeting
GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Samuel Deshayes¹, Venceslas Bourdin ², Christian Creveuil ³, Jonathan Boutemy ¹, Eric Liozon ⁴, Xavier Kyndt ⁵, Laurent Sailler ⁶, Grégory Pugnet ⁶, Hubert de Boysson ¹, Eric Hachulla ⁷, Marc André ⁸, Julie Magnant ⁹, Jacques Boddaert ¹⁰, Olivier Fain ¹¹, Arsène Mékinian ¹¹, Mohamed Hamidou ¹², Loïc Guillevin ¹³, Cédric Landron ¹⁴, Isabelle Marie ¹⁵, Yannick Chène ³, Laurent Becquemont ¹⁶, Céline Verstuyft ² and Boris Bienvenu ¹⁷, ¹Department of Internal Medicine, Caen University Hospital, Caen, France, ²INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Paris, France, ³Biomedical Reserch Unit, Caen University Hospital, Caen, France, ⁴Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, ⁵Department of Internal Medicine and Nephrology, Valenciennes Hospital, Valenciennes, France, ⁶Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ⁷Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France, ⁸Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, ⁹Department of Internal Medicine, Tours University Hospital, Tours, France, ¹⁰Department of Geriatrics, Pitié-Salpêtrière-Charles Foix University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹¹Department of Internal Medicine, Saint Antoine University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, ¹²Department of Internal Medicine, Nantes University Hospital, Nantes, France, ¹³Department of Internal Medicine, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁴Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ¹⁵Department of Internal Medicine, Rouen University Hospital, Rouen, France, ¹⁶INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Le Kremblin Bicêtre, France, ¹⁷Department of Internal Medicine, Saint Joseph Hospital, Marseille, France
Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…
Abstract Number: 377 • 2019 ACR/ARP Annual Meeting
Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Matthew Baker¹, Khushboo Sheth ¹, Julia Simard ², Stanford Shoor ¹ and Mark Genovese ³, ¹Stanford University, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. When it affects the myocardium, it can result in electrical conduction…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 1382 • 2019 ACR/ARP Annual Meeting
The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients
Jacob Greenmyer ¹, John Stacy ¹, James Beal ², Abe Sahmoun ² and Erdal Diri¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Glucocorticoids (GCs) are commonly used in RA patients as remission induction monotherapy or as bridging therapy when starting DMARD/biologic therapy. Despite the ubiquity of…
Abstract Number: 1607 • 2019 ACR/ARP Annual Meeting
Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus patients, particularly those who received corticosteroids are at high risk of avascular necrosis (AVN). A past meta-analysis identified other risk factors…
Abstract Number: 1760 • 2019 ACR/ARP Annual Meeting
Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial
Féline Kroon¹, Marion Kortekaas ¹, Annelies Boonen ², Stephan Böhringer ³, Monique Reijnierse ¹, Frits R Rosendaal ³, Naghmeh Riyazi ⁴, Mirian Starmans ⁵, Franktien Turkstra ⁶, Jende van Zeben ⁷, CF Allaart ⁸ and Margreet Kloppenburg ³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Maastricht University Medical Center, Maastricht, Netherlands, ³Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁴Haga Hospital, The Hague, Netherlands, ⁵Zuyderland Medical Center, Heerlen, Netherlands, ⁶Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁷Sint Franciscus Vlietland Groep, Rotterdam, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Hand osteoarthritis (OA) is a prevalent joint disease with high disease-burden in need for effective therapeutic options. Studies have shown that synovial inflammation is…
Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Michelle Petri¹, Laurence Magder ² and Daniel Goldman ³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…
Abstract Number: 2681 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Mónica Calderón-Goercke¹, Javier Loricera ², DIANA PRIETO- PENA ³, Santos Castañeda ⁴, Vicente Aldasoro Caceres ⁵, Ignacio Villa ⁶, Alicia Humbría ⁷, Clara Moriano ⁸, Susana Romero-Yuste ⁹, Javier Narváez ¹⁰, Catalina Gómez-Arango ¹¹, Eva Perez Pampín ¹², Rafael Melero ¹³, Elena Becerra-Fernández ¹⁴, Marcelino Revenga ¹⁵, Noelia Álvarez-Rivas ¹⁶, Carles Galisteo ¹⁷, Francisca Sivera ¹⁸, Alejandro Olivé-Marqués ¹⁹, María Álvarez del buergo ²⁰, Luisa Marena-Rojas ²¹, Carlos Fernández-López ²², Francisco Navarro ²³, E. Raya ²⁴, Eva Galindez-Agirregoikoa ²⁵, Beatriz Arca ²⁶, Roser Solans-Laqué ²⁷, Arantxa Conesa ²⁸, Cristina Hidalgo ²⁹, Carlos Vazquez ³⁰, Jose Andrés Román-Ivorra ³¹, Pau Lluch ³², Sara Manrique ³³, P. Vela ³⁴, Eugenio de Miguel ³⁵, Carmen Torres-Martín ³⁶, Juan Carlos Nieto ³⁷, Carmen Ordas-Calvo ³⁸, Eva salgado-Pérez ³⁹, Cristina Luna-Gómez ⁴⁰, F. Javier Toyos-Sáenz De Miera ⁴¹, Nagore Fernández-Llanio ⁴², Antonio García ⁴³, Elena Aurrecoechea ⁶, Norberto Ortego ⁴⁴, Francisco Ortiz-Sanjuán ³¹, Montserrat Corteguera ³⁶, Jose Luis Hernández ¹, Miguel Angel González-Gay ⁴⁵ and Ricardo Blanco ⁴⁶, ¹Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Hospital de La Princesa, Madrid, Madrid, Spain, ⁸Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ¹¹Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ¹²Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹³Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁴Hospital de Torrevieja, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramón y Cajal, Madrid, Madrid, Spain, ¹⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ¹⁷Hospital Parc Taulí, Barcelona, Catalonia, Spain, ¹⁸Hospital General Universitario de Elda, Elda, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ²⁰Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ²¹Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ²²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²³Hospital General Universitario de Elche, Alicante, Comunidad Valenciana, Spain, ²⁴Hospital San Cecilio, Granada, Andalucia, Spain, ²⁵Hospital de Basurto, Bilbao, Pais Vasco, Spain, ²⁶Hospital Universitario San Agustín, Avilés, Asturias, Spain, ²⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ²⁸Hospital General Universitario de Castellón, Castellón, Comunidad Valenciana, Spain, ²⁹Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ³⁰Hospital Miguel Servet, Zaragoza, Aragon, Spain, ³¹Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ³²Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, ³³Hospital Regional de Málaga, Málaga, Andalucia, Spain, ³⁴Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ³⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ³⁶Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁷Rheumatology Department. Hospital Gregorio Marañón, Madrid, Madrid, Spain, ³⁸Hospital Cabueñes, Gijón, Asturias, Spain, ³⁹Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ⁴⁰Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, ⁴¹Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, ⁴²Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, ⁴³Hospital Virgen de las Nieves, Granada, Andalucia, Spain, ⁴⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, Granada, Spain, ⁴⁵Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has been approved for the treatment of Giant Cell Arteritis (GCA). It showed to be effective to induce remission, prevent relapses and…
Abstract Number: 2888 • 2019 ACR/ARP Annual Meeting
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
Francine Castillo¹, Adrienne Strait ², Michael Evans ³, Julia Kay ⁴, Milena Gianfrancesco ⁵, Zara Izadi ⁶, Laura Trupin ¹, Mylien Hoang ⁷, James Shalaby ⁸, Gabriela Schmajuk ⁹ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, CA, ²UCSF School of Medicine, San Francisco, CA, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, ⁶UCSF Division of Rheumatology, San Francisco, ⁷Touro University, San Francisco, ⁸Elimu Informatics, San Francisco, ⁹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Prednisone is commonly used to treat rheumatic diseases, yet few comparative effectiveness studies on different dosing regimens are available. Electronic health records (EHR) and…
Abstract Number: 2396 • 2018 ACR/ARHP Annual Meeting
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Lisa Marshall⁴ and Heather Jones⁴, ¹Memorial University of Newfoundland, St John's, NF, Canada, ²IQVIA, Kanata, ON, Canada, ³Global Outcomes & Evidence, Pfizer, Collegeville, PA, ⁴Pfizer, Collegeville, PA
Background/Purpose: In Canada, the pediatric indications of etanercept (ETN) are active ankylosing spondylitis (AS), plaque psoriasis (PsO) and moderate to severely active juvenile idiopathic arthritis…
Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting
Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice
Dimitrios A. Pappas¹, Carol J. Etzel², Jennie Best³, Steve Zlotnick³, Taylor Blachley², Gioia Persuitte² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 2604 • 2017 ACR/ARHP Annual Meeting
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Ronald F van Vollenhoven¹, April Thompson², Bonnie Pobiner², Joe Eastman², Anne Hammer², James Groark³ and Damon Bass³, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK Collegeville, Collegeville, PA
Background/Purpose: Reduced corticosteroid use is considered a key goal in SLE treatment. This concept of ‘steroid-sparing’, seen with intravenous (IV) belimumab based on cumulative steroid…
Abstract Number: 1422 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Dimitrios A. Pappas¹, Chitra Karki¹, Heather J. Litman¹, Taylor Blachley¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Steroids are used to reduce inflammation and pain among rheumatoid arthritis (RA) patients, but they can cause harmful side effects, and in some patients,…
Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting
Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Katherine Liao¹, Carol J. Etzel^2,3, Jeffrey D. Greenberg⁴, Hongshu Guan⁵, Joel Kremer⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
Abstract Number: 214 • 2016 ACR/ARHP Annual Meeting
Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study
Alexandre Dumusc¹, Borbala Pazar Maldonado¹, Charles Benaim², Isabelle Fabreguet¹, Pascal Zufferey¹, Bérengère Aubry-Rozier¹ and Alexander So¹, ¹Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, ²Physical Medicine and Rehabilitation Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland
Background/Purpose: Calcium pyrophosphate crystal-induced arthritis (CPPD) is an acute crystal arthritis, frequently involving the wrist or the knee. Monosodium urate in gout or CPPD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].